Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.

about

Vaccine against arteriosclerosis: an update.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease.

P2860

Q33641227-9FA2213F-B0F9-4878-811F-DE1E15EEE403 Q40100018-7835C861-AD7F-47E1-9E65-E6FE66B3024A Q55107177-2F89FE23-27FE-4A00-BA77-23DE4D942ACD

P2860

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.

Item

http://www.wikidata.org/entity/Q38842531

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.

@en

type

Item

label

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.

@en

prefLabel

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.

@en

P1476

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.

@en

P2093

Michel Farnier

http://www.w3.org/2001/XMLSchema#string

P2860

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Lipoprotein(a) as a cardiovascular risk factor: current status

Current therapies for lowering lipoprotein (a)

PCSK9: a key modulator of cardiovascular health

Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

P2888

s11886-016-0743-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11886-016-0743-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1042920232

http://www.w3.org/2001/XMLSchema#string

P698

27216845

http://www.w3.org/2001/XMLSchema#string

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.

about

P2860

P2860

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698